Seattle Genetics Inc., of Bothell, Wash., closed its public offering of 7.3 million shares of common stock to bring in net proceeds of $37.2 million for clinical and preclinical development of its existing product candidates, as well as manufacturing of clinical-grade materials and for other research and development activities...Net proceeds will be used for general working capital. (See BioWorld Today, March 29, 2006

Net proceeds will be used to support product commercialization, clinical trials and general corporate purposes. (See BioWorld Today, March 27, 2006...The company, which develops immunotherapy products to treat cancer, intends to use the net proceeds for clinical trial activities and corporate purposes

Seattle Genetics Inc., of Bothell, Wash., received net proceeds of $37.2 million from its offering of 7.3 million shares...Money will be used to fund clinical and preclinical development of its existing product candidates, as well as manufacturing of clinical-grade materials, and for other research and development initiatives

In the middle of 2005, the company raised about $75.8 million in net proceeds through a public stock offering with other institutional investors. (See BioWorld Today, July 18, 2005.) Renaud said Keryx would burn through about $40 million this year, a slight increase over last year, as its clinical trial costs continue to mount...Net proceeds are expected to total about $47 million and will fund ongoing research and clinical development activities for its four lead product candidates, all of which

Net proceeds will be used to fund the preclinical and clinical development of the company’s product candidates and for capital and general corporate purposes...Net proceeds are expected to total about $4.7 million, and will be used to fund Viragen’s ongoing research and development plans, regulatory strategies, and to proceed with the international marketing of Multiferon in approved territories

The offering is being made as a private placement, and net proceeds will be used in part to fund the company’s acquisition of Lake Forest, Ill.-based American Medical Instruments Holdings Inc., expected to close in late March...Fisher is a leading provider of products and services to the scientific and clinical laboratory markets

The overall clinical response rate increased from 49 percent at month three following Rituxan alone to 65 percent following the initiation of FavId...Favrille’s other clinical pipeline product, FAV-201, is expected to enter a Phase I/II trial in the first half of this year for T-cell lymphoma...RegeneRx is developing TB4, a 43 amino acid peptide, and is sponsoring three Phase II chronic dermal wound healing clinical trials.

Clinical testing with NPI-2358 will begin in solid tumors...The financing is expected to fund clinical work for both compounds through Phase I. After that, "it’s an open question," he said...We have two lead clinical compounds, backup compounds and others in the pipeline that could be developed if we so desire

CytRx Corp., of Los Angeles, entered into definitive agreements with a group of institutional investors to raise about $13.4 million from the private sale of common stock and warrants for the purchase of common stock, with net proceeds to CytRx of about $12.4 million after expenses...Proceeds will fund ongoing clinical development, the company said, notably the Phase II trial with its lead small molecule, arimoclomol, targeting amyotrophic lateral sclerosis...The price is calculated as the average of

Its lead candidate, cethromycin, is a ketolide antibiotic in late-stage clinical development for respiratory tract infections...The clinical cure rate at the test-of-cure visit is the primary endpoint of the trial, which is powered to demonstrate non-inferiority at the 95 percent confidence interval...The Exton, Pa.-based drug delivery firm plans to use the net proceeds for working capital, acquisitions, in-licensing of products or technologies and capital expenditures

If satisfactory progress continues in 2007, CFFT will support Copernicus’ CF gene therapy development and clinical programs through completion of a multiple-dose Phase II trial...Immtech International Inc., of Vernon Hills, Ill., closed its underwritten public offering of 2 million shares for gross proceeds of $16 million, with net proceeds totaling about $14.8 million

Net proceeds are expected to be about $30.3 million, and will go toward ongoing development of Valera’s implantable drug pipeline, including VP002, which started a pivotal trial in September 2004 for hormonal treatment of central precocious puberty...IPO funds also will support clinical trials for VP006 in nocturnal enuresis, as well as Phase IIb trials for VP003 in acromegaly, and Phase I/II studies for VP004 in addiction disorders

Net proceeds from the offering are estimated at $50.8 million, or $58.4 million if underwriters exercise a 960,000-share overallotment option in full...According to its prospectus, Genitope intends to use the funds to support clinical trials and other expenses related to the potential commercialization of MyVax, a patient-specific immunotherapy designed to activate the immune system to identify and attack cancer cells

Net proceeds, estimated at about $24.5 million, will enable the firm to finish its Phase III trials in Huntington's disease with the lead compound Miraxion, which are due to finish late next year or early 2007...Proceeds will be used for working capital, including support of clinical trials for the company's lead product, its Selective Electrochemical Tumor Ablation System (SETAS), and general corporate purposes

Net proceeds from the offering are expected to be about $48.2 million, if underwriters exercise the overallotment in full...Its clinical programs include GTP-010 for irritable bowel syndrome and GTP-200 for the treatment of cachexia and other catabolic syndromes

Net proceeds from the offering will be used for general corporate purposes, including clinical trials, research and development activities, capital expenditures, facilities expansion and to meet working capital needs

According to its prospectus, net proceeds of about $81.1 million will go toward clinical trials, research and development, general corporate purposes, capital expenditures, acquisitions of new technologies and working capital

The company expects to use proceeds for general corporate purposes, including expanding commercial and marketing efforts, increasing working capital, funding clinical development, and acquiring new products or technologies...The financing will help Tessera to prepare the technology for clinical trials and commercialization.

Clinical trials of SNS-314 are expected to begin next year...Net proceeds are expected to total about $14 million and will fund ongoing product development, including the company's clinical trials in cancer and cardiac disease, and the expansion of manufacturing capabilities and general corporate purposes